Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 15/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | QPCT | Q16769 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133279 | 0.98 | POLB (0.51) | POLBPDE4AALDH1A1MAPTQPCT | |
| SCHEMBL3131100 | 0.95 | POLB (0.44) | POLBPDE4AALDH1A1MAPTQPCT | |
| SCHEMBL3120566 | 0.86 | PDE4A (0.45) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL986245 | 0.85 | PDE4A (0.60) | POLBPDE4AALDH1A1MAPTPDE4D | |
| SCHEMBL986248 | 0.84 | PDE4A (0.58) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL3118145 | 0.82 | POLB (0.47) | POLBPDE4AALDH1A1MAPTQPCT | |
| SCHEMBL1157332 | 0.81 | PDE4A (0.58) | POLBPDE4APDE4DPDE4BPDE4C | |
| SCHEMBL3122756 | 0.81 | PDE4B (0.45) | POLBPDE4AALDH1A1MAPTPDE4D | |
| SCHEMBL1157253 | 0.81 | TUBB4A (0.57) | POLBALDH1A1MAPTPDE4B | |
| SCHEMBL3128693 | 0.81 | POLB (0.46) | POLBPDE4AQPCTPDE4DPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | POLB 1798/4885PDE4A 1/4885ALDH1A1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.